Immunotherapy for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Nanomedicine
• Immunotherapy

Background:

• Triple-negative breast cancer (TNBC) presents significant challenges due to tumor heterogeneity, aggressiveness, and high metastatic potential.
• TNBC's lack of targeted receptors (ER, PR, HER2) limits conventional therapies, contributing to higher patient mortality.
• A heightened immune response in TNBC suggests immunotherapy as a viable therapeutic strategy.

Purpose of the Study:

• To review the principles and latest advancements in nanocarrier-based drug delivery systems for TNBC immunotherapy.
• To explore the potential of combining nanomedicine-based immunotherapy with other treatment modalities for TNBC.

Main Methods:

• Review of current literature on nanocarriers, immunotherapy, and combination therapies for TNBC.
• Analysis of the enhanced permeability and retention (EPR) effect of nanomedicines in cancer therapy.
• Discussion of immune checkpoint blockade, adoptive T-cell, and tumor vaccine immunotherapies in the context of TNBC.

Main Results:

• Nanomedicines, utilizing the EPR effect, show potential for improving drug delivery in TNBC.
• Combination therapies involving immunotherapy with chemotherapy, PDT, PTT, or SDT may offer synergistic effects.
• Various immunotherapy approaches, including IC blockade, adoptive T-cell, and vaccine therapies, are being investigated for TNBC.

Conclusions:

• Nanocarriers are promising drug delivery systems for enhancing TNBC immunotherapy.
• Combination strategies hold potential for synergistic therapeutic outcomes in TNBC treatment.
• Further research into nanomedicine-based immunotherapy is crucial for advancing TNBC treatment options.